She is the Chairperson, Editorial Board, Blueprint newspaper.
She is the immediate past Commissioner of Information, Kogi State.
She is the founder and Editor-in-Chief of Verity News Online.
She is one of the most recognized women journalists in Northern Nigeria.
She writes a syndicated weekly column, “Rendezvous”, which she started when she was working with Daily Trust.
Many prominent journalists, including foremost editors, have benefitted from her mentorship.
She is an alumnus of the US Department of State’s International Visitors Leadership Programme.
She was pioneer Production Editor of Weekly Trust (now Daily Trust on Saturday).
She was Deputy Editor Daily Trust, Editor Weekly Trust, Deputy Managing Editor and Deputy Chairman of the Editorial Board at Media Trust Limited.
BRCA-related cancers alone (
P=0.008); and those who showed sensitivity to platinum-based chemotherapy, at 4.1 months versus 2.2 months in patients with platinum-resistant disease (
P=0.01). The findings suggest that the PARP inhibitor olaparib may have therapeutic value for patients with platinum-sensitive PDAC [pancreatic ductal adenocarcinoma] with specific DDR-GAs other than germline
BRCA variants, the authors concluded.
OS reached 13.6 months in the DDR-GA group (95% CI 9.69-not reached) and was significantly longer for patients with platinum-sensitive versus platinum-resistant disease (10.5 vs 5.4 months,
P=0.03).
The phase III POLO study showed that PARP inhibition with olaparib as maintenance therapy improved PFS versus placebo in advanced pancreatic cancer patients with germline
email article
Elevated BMI was tied to improved survival in metastatic renal cell carcinoma (RCC) patients treated with immune checkpoint inhibitors, a retrospective study found.
In the analysis of more than 700 metastatic RCC patients who received PD-1/L1 immunotherapies, those with a BMI of 25 or greater had significantly longer overall survival (OS), with 1-year rates of 79% versus 66% for those with a BMI below that cutoff (HR 0.75, 95% CI 0.57-0.97,
P=0.03), Toni Choueiri, MD, of Dana-Farber Cancer Institute in Boston, and colleagues reported. These findings are consistent with the obesity paradox that was previously seen during the VEGF-targeted therapy era, the group wrote in
FDA OKs Peptide-Drug Conjugate for Multiple Myeloma medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
email article
After close to a decade at the helm, Richard Schilsky, MD, has retired from his role as chief medical officer of the American Society of Clinical Oncology (ASCO).
His legacy as the organization s first CMO will be what he calls the ASCO research enterprise launching ASCO s first-ever clinical trial, increasing its ability to conduct observational studies, and tapping into the 40,000-person membership for original survey-based research. It was clear that while ASCO was a tremendous vehicle to disseminate and amplify research findings that were generated by various entities, ASCO itself didn t actually do any research to contribute any knowledge to the field, Schilsky told